ALLO insider transaction filings
Allogene Therapeutics, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-06. Screen ALLO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Roberts Zachary — President and CEO | Grant/award (A): 134,530 (derivative) @ $0 · Grant/award (A): 476,190 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Barrett Elizabeth A. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | MESSEMER DEBORAH M. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Mayo Stephen — Director | Grant/award (A): 144,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | WITTE OWEN N. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Humer Franz B — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Kazam Joshua A — Director | Option exercise (M): 47,700 @ $0 · Option exercise (M): 47,700 (derivative) @ $0 · Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | SATO VICKI L — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Yoshiyama Annie — SVP, Finance | Sale (S): 9,586 @ $2.31 | EDGAR |
| 2026-04-02 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 2,867 @ $2.50 | EDGAR |
| 2026-03-18 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 4,835 @ $2.47 | EDGAR |
| 2026-03-18 | 4 | Chang David D — President and CEO, Director | Sale (S): 47,763 @ $2.47 | EDGAR |
| 2026-03-04 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 7,132 @ $2.60 | EDGAR |
| 2026-02-04 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 7,549 @ $1.73 · Grant/award (A): 373,757 (derivative) @ $0 · Grant/award (A): 105,720 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Yoshiyama Annie — SVP, Finance | Sale (S): 4,167 @ $1.72 · Grant/award (A): 179,691 (derivative) @ $0 · Grant/award (A): 50,827 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Roberts Zachary — EVP of R&D | Sale (S): 35,700 @ $1.77 · Grant/award (A): 718,763 (derivative) @ $0 · Grant/award (A): 203,307 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Chang David D — President and CEO, Director | Sale (S): 95,269 @ $1.80 · Grant/award (A): 1,387,931 (derivative) @ $0 · Grant/award (A): 392,586 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Parker Geoffrey M. — CHIEF FINANCIAL OFFICER | Sale (S): 24,001 @ $1.76 · Grant/award (A): 539,072 (derivative) @ $0 · Grant/award (A): 152,480 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Douglas Earl Martin — SVP, General Counsel | Sale (S): 22,900 @ $1.76 · Grant/award (A): 539,072 (derivative) @ $0 · Grant/award (A): 152,480 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Belldegrun Arie — Director | Grant/award (A): 929,913 (derivative) @ $0 · Grant/award (A): 263,033 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Roberts Zachary — EVP of R&D | Sale (S): 26,269 @ $1.56 | EDGAR |
| 2025-12-22 | 4 | Kazam Joshua A — Director | Option exercise (M): 47,700 @ $0 · Option exercise (M): 47,700 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 786 @ $1.22 | EDGAR |
| 2025-10-23 | 4 | Parker Geoffrey M. — CHIEF FINANCIAL OFFICER | Sale (S): 36,744 @ $1.26 | EDGAR |
| 2025-06-23 | 4 | MESSEMER DEBORAH M. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Barrett Elizabeth A. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Mayo Stephen — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | WITTE OWEN N. — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Humer Franz B — Director | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Kazam Joshua A — Director | Grant/award (A): 94,500 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | SATO VICKI L — Director | Grant/award (A): 144,400 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | MESSEMER DEBORAH M. — Director | Sale (S): 36,885 @ $1.42 | EDGAR |
| 2025-04-23 | 4 | Yoshiyama Annie — SVP, Finance | Sale (S): 9,601 @ $1.41 | EDGAR |
| 2025-03-18 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Sale (S): 5,488 @ $1.98 | EDGAR |
| 2025-03-18 | 4 | Chang David D — President and CEO, Director | Sale (S): 46,668 @ $1.96 | EDGAR |
| 2025-03-05 | 4 | Beneski Benjamin Machinas — SVP, Chief Technical Officer | Grant/award (A): 31,755 @ $0 · Grant/award (A): 112,339 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | MESSEMER DEBORAH M. — Director | Sale (S): 13,313 @ $2.43 | EDGAR |
| 2025-02-05 | 4 | Roberts Zachary — EVP of R&D | Sale (S): 18,832 @ $1.70 | EDGAR |
| 2025-02-05 | 4 | MOORE TIMOTHY L. — Chief Technical Officer | Sale (S): 14,746 @ $1.71 | EDGAR |
| 2025-02-05 | 4 | Chang David D — President and CEO, Director | Sale (S): 46,003 @ $1.68 | EDGAR |
| 2025-02-05 | 4 | Parker Geoffrey M. — CHIEF FINANCIAL OFFICER | Sale (S): 4,361 @ $1.73 | EDGAR |
| 2025-02-05 | 4 | Douglas Earl Martin — SVP, General Counsel | Sale (S): 6,404 @ $1.71 | EDGAR |
| 2025-01-28 | 4 | Roberts Zachary — EVP of R&D | Grant/award (A): 173,913 @ $0 · Grant/award (A): 614,844 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Parker Geoffrey M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 173,913 @ $0 · Grant/award (A): 614,844 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Douglas Earl Martin — SVP, General Counsel | Grant/award (A): 144,928 @ $0 · Grant/award (A): 512,370 (derivative) @ $0 | EDGAR |
Recent 8-K events — Allogene Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-14 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALLO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →